Oxehealth Wins Funding to Trial Camera-based Health Monitoring with Broadmoor Hospital
News Dec 30, 2014
Oxehealth has been awarded funding by Innovate UK, to develop its vital sign monitoring technology, in collaboration with Broadmoor Hospital.
Oxehealth, the spin out from the University of Oxford’s Institute of Biomedical Engineering and Oxford University Hospitals NHS Trust, has received the funding to develop and test its Oxecam technology for monitoring the vital signs of patients in secure rooms.
The six-month project, which commenced on 1st October, is being run in conjunction with Broadmoor Hospital, the renowned high secure psychiatric hospital. If successful it will be followed by steps to develop a finished version of the Oxecam for secure rooms.
The use of the Oxecam is intended to improve the care of patients in secure rooms. It aims to improve their safety and well-being, and will save money by simplifying patient safety checks.
“In a world in which people are choosing to install and use cameras in ever more settings, Oxehealth’s technology will invisibly monitor personal health enabling us all to live safer, healthier and longer,” said Jonathan Chevallier, CEO at Oxehealth. “This trial at Broadmoor Hospital is a demonstration of how our technology works in secure environments, but it can equally be deployed in every home, vehicle and hospital worldwide.”
The project will test in a real-life setting how the Oxecam can improve upon the current approach of periodic observations by staff, which can be subject to inconsistencies or disturb the patients, especially at night. It will do this by using sophisticated algorithms to process video images and provide estimates of vital signs on a continuous basis.
The algorithms monitor the patient’s movement and breathing for signs of distress, as well as heart rate and other parameters that can be measured to assess the patient’s wellbeing.
“Using technology to improve the patient experience and to promote patient safety is exactly what all providers of healthcare are hoping to achieve”, said Dr Amlan Basu, Clinical Director at Broadmoor.
“We are enjoying working with the Oxehealth team on this project, not least due to our shared enthusiasm for this kind of innovative work. The potential to transfer this technology to other settings is also tremendously exciting.”
The project will be jointly run by Oxehealth and Broadmoor Hospital, with algorithm tuning supported by researchers at the Institute of Biomedical Engineering, University of Oxford.
A new colorectal cancer vaccine showed positive results in the phase 1 clinical trial to demonstrate that the approach is safe. The patients treated had no signs of serious adverse events and samples of their blood contained markers of immune activation – an early indication that the vaccine could activate immune cells to fight colorectal tumors and metastases.READ MORE